Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loteprednol Etabonate Gel 0.38% for post-cataract inflammation and pain
NCT02786901Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Jun 2016
- Primary completion
- Jun 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of loteprednol etabonate ophthalmic gel 0.38% in ocular inflammation, sponsored by Bausch + Lomb. Started Jun 2016; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT02786901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02786901.